Is capmatinib included in medical insurance?

Capmatinib (Capmatinib) TKI was first discovered in type ib parathyroid tumors in 2011, and was approved by the US Food and Drug Administration (FDA) in August 2022 for the treatment of advanced non-small cell lung cancer with exon 14 skipping mutations in parathyroid tumors. Preclinical and early-stage studies in the GEOMETRY mono-1 study demonstrated beneficial efficacy against MET exon 14 skipping mutations, leading to FDA approval of capmatinib and the Foundation One CDx assay as its adjunctive diagnostic test. The current and future development directions of capmatinib focus on improving the efficacy, overcoming resistance to capmatinib, and finding new indications for capmatinib.

Capmatinib is only available by prescription, and treatment should be started and supervised by a doctor experienced in the use of cancer drugs. Before starting treatment, patients should undergo testing to confirm the METex14 skipping mutation in their cancer. Capmatinib is available as an oral tablet. The recommended dose is 400 mg twice daily. Treatment with capmatinib can be continued as long as the patient is benefiting from it. If certain side effects occur, your doctor may decide to reduce your dose, or interrupt or stop treatment with capmatinib.

Although the innovative drug capmatinib has not yet officially entered the domestic market and is therefore not included in the scope of medical insurance, the original drug capmatinib can already be found in Hong Kong. Overseas, a European version of the original drug capmatinib is sold. There are also generic capmatinib drugs available overseas. The ingredients are basically the same as those of the original drug, but there may be differences in price. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.